
    
      This is a placebo-controlled, randomized, double-blind, parallel group, comparative study,
      when patients with chronic idiopathic intestinal pseudo-obstruction(CIIPO) or patients with
      chronic intestinal pseudo-obstruction (CIPO), secondary to the onset of systemic scleroderma,
      are administered rifaximin at 400 mg 3 times daily for 4 weeks. In addition, the time course
      of symptoms of the patients are to be confirmed for 8 weeks after the end of administration.
    
  